Dimerix Ltd has released a press release.
Quarterly Commentary & Appendix 4C
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Dimerix
- DMX-200 Clinical Trial Update
- Dimerix Completes $2.5m Placement
- Dimerix Holds Pre-IND Meeting on DMX-200 With FDA
- New Drug Pipeline Candidate DMX-700 & Company Update
- DMX-200 Phase 2 Clinical Study in DKD Completes Recruitment
Later from Dimerix
- Half Yearly Report and Accounts
- DMX-200 Treatment Continued Under TGA Special Access Scheme
- R&D Tax Incentive Facility
- Global REMAP-CAP Platform Trial Protocol To Include DMX-200
- Last Patient Completes Dosing in FSGS Phase 2 Clinical Study
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix